Clinical trials: Anti-obesity Agents
Obesity & Overweight
Retrospective Evaluation of Sibutramine-Topiramate Therapy for Obesity in Real-World Outpatient Practice
This retrospective real-world cohort study aims to evaluate the effectiveness, safety, and tolerability of the combination of sibutramine and topiramate in the treatment of obesity and overweight associated with metabolic…
- Trial name
- SIBUTAMATE (NCT07588750)
- Testing
- Sibutramine + Topiramate
- Where
- Brazil
- Volunteers
- 278 people
- Sponsor
- Falquetomed
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Obesity
A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety
This primary purpose of this study is to determine if ATHX-105 phosphate causes weight loss over a 12-week period.
- Trial name
- NCT00735683
- Testing
- ATHX-105 phosphate
- Sponsor
- Healios K.K.
Lymphocytes, Weight Loss
Effect of Weight Reduction on Immunity
This study included two groups of premenopausal healthy obese women. Experimental group underwent a weight loss program involved a low calorie diet plus anti-obesity drugs and moderate physical activity and control group…
- Conditions
- Lymphocytes, Weight Loss, Viral Diseases, Immunity
- Trial name
- NCT03336086
- Testing
- weight loss program
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Shiraz University of Medical Sciences
Obesity and Obesity-related Medical Conditions, Bariatric Surgery
Monitoring Nutritional Consequences of Obesity Treatment on Women's Health
The goal of this observational study is to investigate the long-term effect of obesity treatments on the health of women. This study will specifically focusses on the effects on nutritional intake, nutritional status…
- Conditions
- Obesity and Obesity-related Medical Conditions, Bariatric Surgery, Anti-obesity Agents, Body Composition
- Trial name
- MONUCO (NCT06945016)
- Where
- Netherlands
- Volunteers
- 1,150 people
- Sponsor
- Wageningen University and Research
Obesity
Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery
This is a randomized controlled trial employing a Sequential Multiple Assignment Randomized Trial (SMART) design to test whether pharmacotherapy, in conjunction with lifestyle counseling, can reverse weight regain after bariatric…
- Trial name
- PROJECT-BARI (NCT05975580)
- Testing
- Topiramate, Phentermine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of California, Irvine
Obesity, Overweight
Teaching Obesity Treatment Options to Adult Learners (TOTAL): A Multisite RCT
Nearly 8 in 10 Veterans meet criteria for overweight/obesity. Three evidence-based treatment options are available within VA (behavioral weight management [MOVE!], obesity medications, and bariatric surgery).
- Trial name
- TOTAL (NCT05346575)
- Testing
- Teaching Obesity Treatments to Adult Learners (TOTAL), Usual care
- Where
- 2 sites in United States
- Volunteers
- 440 people
- Sponsor
- VA Office of Research and Development
C-reactive Protein, Inflammation
Obesity, Inflammation and Oxidative Stress
The purpose of this study is to determine whether or not Vitamin C (1000 mg/day) can reduce markers of inflammation, especially C-reactive protein (CRP), in obese persons with baseline CRP greater than 1 mg/dl.
- Conditions
- C-reactive Protein, Inflammation, Obesity, Oxidative Stress
- Trial name
- NCT01028976
- Testing
- Vitamin C (ascorbic acid)
- Where
- United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Type 2 Diabetes, Obesity
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
To determine if the EndoBarrier safely and effectively improves glycemic control in obese subjects with type 2 diabetes
- Trial name
- ENDO (NCT01728116)
- Testing
- EndoBarrier
- Where
- 25 sites in United States
- Volunteers
- 325 people
- Sponsor
- Morphic Medical Inc.
Multiple Sclerosis, Long COVID
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making…
- Conditions
- Multiple Sclerosis, Long COVID, Long Covid19, Obese
- Trial name
- NCT06171152
- Testing
- Liraglutide Pen Injector [Saxenda], Medication Diary
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Anti Obesity Agent
Inhibition of Food Intake in Response to Oral GLP-1 and Peptide YY3-36
Interaction of GLP-1 and PYY3-36 in the inhibition of food intake in healthy subjects
- Trial name
- NCT00822705
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Cocaine Use Disorders
A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence
The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, bupropion and naltrexone, as a pharmacotherapy for cocaine dependence.
- Trial name
- NCT01739192
- Testing
- Bupropion
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Craig Rush
Obesity (Disorder)
Mechanisms of Weight Loss: Tirzepatide vs Semaglutide
The goal of this clinical trial is to determine if there are differences in the effect of 12 weeks of tirzepatide versus semaglutide on energy balance in adults with obesity and without known diabetes.
- Trial name
- JOULE3 (NCT07900074)
- Testing
- Tirzepatide, Semaglutide
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- McMaster University
Overweight and Obesity
Trial to Examine the Effect of Natural Anti- Obesity Agent (Phaseolus Vulgaris) Among Women of Lahore
This double-blind randomized placebo-controlled trial will test the hypothesis that administration of Phaseolus Vulgaris supplementation to women in Lahore, Pakistan, who are overweight will induce the weight loss (Primary…
- Trial name
- PVE-AO (NCT05451927)
- Testing
- Phaseolus Vulgaris
- Where
- 2 sites in Pakistan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hafiza Aisha Sadiqa
Healthy
Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers
This is a Phase 1, open-label, randomized, single-dose, 2-way crossover study in healthy adult subjects to assess the bioequivalence of naltrexone SR/bupropion SR combination trilayer tablets prepared at two different…
- Trial name
- NCT02259179
- Testing
- Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Orexigen Therapeutics, Inc
Sleep Apnea, Obstructive Sleep Apnea
Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients
This RCT explores the efficacy of Zonisamide (Zonegran®)on overweight/obese in patients with moderate to severe obstructive sleep apnea.
- Conditions
- Sleep Apnea, Obstructive Sleep Apnea, Obesity
- Trial name
- NCT01765608
- Testing
- Zonisamide, nCPAP
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Göteborg University
Overweight and Obesity, Hypercholesterolemia
Effect of Silibinin(A) as a Potential Anti-obesity Agent
Our preliminary reports have found in silico and in vitro that the milk thistle derivative Silibinin(A) is able to inhibit pancreatic lipase, in a similar way that the classical anti-obesity drug orlistat.
- Conditions
- Overweight and Obesity, Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT05069298
- Testing
- Silibinin A
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Católica San Antonio de Murcia
Overweight, Obesity
Safety and Efficacy of Medicinal Plant Extract in Overweight and Obese Participants.
The purpose of this randomized , double -blind clinical trial is to evaluate the efficacy and safety of a daily administration of Nitraria retusa extract in overweight and obese participants, during 10 days.
- Trial name
- NCT05824039
- Testing
- Tea infusion
- Where
- Tunisia
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Laouani Aicha
Endometrial Cancer, Atypical Hyperplasia
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
The incidence of endometrial cancer is increasing at an alarming rate. This trend parallels the rising rate of obesity, the most significant risk factor for endometrial cancer.
- Conditions
- Endometrial Cancer, Atypical Hyperplasia, Fertility Perservation
- Trial name
- WE-FiERCE (NCT06073184)
- Testing
- Wegovy, Mirena
- Where
- Canada
- Volunteers
- 71 people
- Sponsor
- GynOncTrials
Hormone-receptor-positive Breast Cancer, Early Breast Cancer
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial
The CLARA trial is a phase II window-of-opportunity trial evaluating how a commonly used weight-loss medication (tirzepatide, a GLP-1/GIP receptor agonist) affects breast cancer biology, alone and in combination with standard…
- Trial name
- CLARA (NCT07676331)
- Testing
- Tirzepatide, Letrozole (Aromatase Inhibitors)
- Volunteers
- 168 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven